Destiny Pharma plc (GB:DEST) has released an update.
Destiny Pharma plc, a biotech firm specializing in medicines to combat life-threatening infections, has announced the cessation of trading its shares on the AIM market as of August 12, 2024. The company will transition to a private entity named Destiny Pharma Limited and commence trading on the JP Jenkins securities matching platform from August 13. Shareholders are advised to follow the company’s news alerts for updates post-cancellation and can trade shares through their existing UK regulated stockbroker.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.